Cowen Inc’s Tvardi Therapeutics TVRD Stock Holding History

Cowen Inc’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-222	Closed	-$123K	–	329
2017 Q2	$123K	Buy	+222	New	+$141K	0.01%	285

Other funds holding TVRD

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cowen Inc's TVRD Position: Q3 2017 in Review

Cowen Inc sold out of Tvardi Therapeutics (TVRD) in Q3 2017, closing a stake of 222 shares — an estimated $123K sold.

Cowen Inc first reported a position in TVRD in Q2 2017 and held it in 1 quarter. The position peaked at $123K in Q2 2017. 121 funds tracked by Wall St. Rank hold TVRD as of Q3 2017.

Cowen Inc reported no remaining Tvardi Therapeutics position as of Q3 2017 after selling out during the quarter.
Cowen Inc sold 222 Tvardi Therapeutics shares in Q3 2017, an estimated $123K.
Cowen Inc first reported a position in Tvardi Therapeutics in Q2 2017 and held it in 1 quarter.
Cowen Inc's Tvardi Therapeutics position peaked at $123K in Q2 2017.
121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2017.

Based on Cowen Inc's 13F filing for Q3 2017, filed 14 Nov 2017.